Results 111 to 120 of about 87,437 (368)

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner   +7 more
wiley   +1 more source

NASA Light-Emitting Diodes for the Prevention of Oral Mucositis in Pediatric Bone Marrow Transplant Patients [PDF]

open access: yes, 2002
Objective: The purpose of this study was to determine the effects of prophylactic near-infrared light therapy from light-emitting diodes (LEDs) in pediatric bone marrow transplant (BMT) recipients.
Barbeau, Lori   +10 more
core   +1 more source

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia

open access: yesDrugs, 2018
VYXEOS™ is a liposomal-encapsulated formulation of daunorubicin and cytarabine delivering a fixed, synergistic 1:5 molar ratio (hereafter referred to as daunorubicin/cytarabine liposome).
Hannah A. Blair
semanticscholar   +1 more source

Germline variants observed in pediatric cancer patients related to hereditary breast and ovarian cancer in adults

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Investigating the spectrum of (likely) pathogenic germline variants (LP/PVs) in hereditary breast and ovarian cancer (HBOC) genes in pediatric malignancies by unselected genotyping identified 44% (12/27) of clinically unsuspected cases. Burden testing demonstrated considerable associations between monoallelic LP/PVs in five HBOC genes and ...
Katharina Daugs   +11 more
wiley   +1 more source

The blind men and the AML elephant:can we feel the progress? [PDF]

open access: yes, 2016
The pharmacological therapy of non-promyelocytic acute myeloid leukemia (AML) has remained unchanged for over 40 years with an anthracycline–cytarabine combination forming the backbone of induction treatments.
A Wanquet   +38 more
core   +3 more sources

The Contribution of Cholesterol and Squalene Synthase in Cancer: Molecular Mechanisms, Lipid Rafts and Therapeutic Approaches

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT A plethora of cellular signaling pathways are dysregulated in cancer cells, promoting carcinogenesis and migration. Cholesterol has recently been linked to cancer by several subcellular mechanisms, especially by its involvement in the formation of lipid rafts, which promote oncogenic signaling and cancer cell invasion. Squalene synthase (SQS),
Danai Mavridi   +2 more
wiley   +1 more source

Biological aspects of mTOR in leukemia [PDF]

open access: yes, 2018
The mammalian target of rapamycin (mTOR) is a central processor of intra-and extracellular signals, regulating many fundamental cellular processes such as metabolism, growth, proliferation, and survival.
Bianchi, Mp   +5 more
core   +1 more source

Inhibition of Tunneling Nanotube (TNT) Formation and Human T-cell Leukemia Virus Type 1 (HTLV-1) Transmission by Cytarabine

open access: yesScientific Reports, 2018
The human T-cell leukemia virus type 1 (HTLV-1) is highly dependent on cell-to-cell interaction for transmission and productive infection. Cell-to-cell interactions through the virological synapse, biofilm-like structures and cellular conduits have been ...
M. Omsland   +8 more
semanticscholar   +1 more source

Nanosensors in Leukemia Management: Pioneering Real‐Time Biomarker Detection for Precision Oncology

open access: yesNano Select, EarlyView.
This review highlights pioneering nanosensors designed for real‐time leukemia biomarker detection, integrating advanced nanomaterials such as liposomes, polymeric nanoparticles and quantum dots. It examines electrochemical, optical and magnetic detection mechanisms, the applications across AML, ALL, CML, and CLL subtypes, and clinical translation ...
Hamed Soleimani Samarkhazan   +5 more
wiley   +1 more source

Integrating Phase 2 into Phase 3 based on an Intermediate Endpoint While Accounting for a Cure Proportion -- with an Application to the Design of a Clinical Trial in Acute Myeloid Leukemia

open access: yes, 2019
For a trial with primary endpoint overall survival for a molecule with curative potential, statistical methods that rely on the proportional hazards assumption may underestimate the power and the time to final analysis.
Heinzmann, Dominik   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy